Small molecules: towards clinical development
The potential of nanomedicine to provide therapeutic benefits over conventional drug formulations has been proven with other drugs in the market. One example of success is DOXIL®, a liposome-based doxorubicin formulation which improves pharmacokinetic profile. In the same direction, DIVERSA aims to bridge the gap [...]